|
1
|
Gutman M, Inbar M, Chaitchik S, Merhav A,
Pausner D, Skoznik Y, Ilie B, Rozin RR and Klausner JM: Malignant
melanoma of the mucus membranes. Eur J Surg Oncol. 18:307–312.
1992.PubMed/NCBI
|
|
2
|
Banerjee SS and Harris M: Morphological
and immunophenotypic variations in malignant melanoma.
Histopathology. 36:387–402. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sheibani K and Battifora H: Signet-ring
cell melanoma. A rare morphologic variant of malignant melanoma. Am
J Surg Pathol. 12:28–34. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rutten A, Huschka U, Requena C,
Rodriguez-Peralto JL and Requena L: Primary cutaneous signet-ring
cell melanoma: A clinico-pathologic and immunohistochemical study
of two cases. Am J Dermatopathol. 25:418–422. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kacerovska D, Sokol L, Michal M and
Kazakov DV: Primary cutaneous signet-ring cell melanoma with
pseudoglandular features, spindle cells and oncocytoid changes. Am
J Dermatopathol. 31:81–83. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bastian BC, Kutzner H, Yen T and LeBoit
PE: Signet-ring cell formation in cutaneous neoplasms. J Am Acad
Dermatol. 41:606–613. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nakhleh RE, Wick MR, Rocamora A, Swanson
PE and Dehner LP: Morphologic diversity in malignant melanomas. Am
J Clin Pathol. 93:731–740. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ohsie SJ, Sarantopoulos GP, Cochran AJ and
Binder SW: Immunohistochemical characteristics of melanoma. J Cutan
Pathol. 35:433–444. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chang AE, Karnell LH and Menck HR: The
National Cancer Data Base report on cutaneous and noncutaneous
melanoma: A summary of 84,836 cases from the past decade. The
American College of Surgeons Commission on Cancer and the American
Cancer Society. Cancer. 83:1664–1678. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo J, Si L, Kong Y, Flaherty KT, Xu X,
Zhu Y, Corless CL, Li L, Li H, Sheng X, et al: Phase II,
open-label, single-arm trial of imatinib mesylate in patients with
metastatic melanoma harboring c-Kit mutation or amplification. J
Clin Oncol. 29:2904–2909. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moreira A, Heinzerling L, Bhardwaj N and
Friedlander P: Current melanoma treatments: Where Do We Stand?
Cancers. 13:2212021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang HM, Hsiao SJ, Schaeffer DF, Lai C,
Remotti HE, Horst D, Mansukhani MM and Horst BA: Identification of
recurrent mutational events in anorectal melanoma. Mod Pathol.
30:286–296. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kocovski L and Alowami S: Signet-ring cell
melanoma: A potential diagnostic pitfall. Am J Dermatopathol.
36:985–988. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ben-Izhak O, Stark P, Levy R, Bergman R
and Lichtig C: Epithelial markers in malignant melanoma. A study of
primary lesions and their metastases. Am J Dermatopathol.
16:241–246. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Blecker D, Abraham S, Furth EE and Kochman
ML: Melanoma in the gastrointestinal tract. Am J Gastroenterol.
94:3427–3433. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Khalid U, Saleem T, Imam AM and Khan MR:
Pathogenesis, diagnosis and management of primary melanoma of the
colon. World J Surg Oncol. 9:142011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
LiVolsi VA, Brooks JJ, Soslow R, Johnson
BL and Elder DE: Signet cell melanocytic lesions. Mod Pathol.
5:515–520. 1992.PubMed/NCBI
|
|
18
|
Bonetti F, Colombari R, Zamboni G and
Chilosi M: Signet ring melanoma, S-100 negative. Am J Surg Pathol.
13:522–523. 1989. View Article : Google Scholar : PubMed/NCBI
|
